Table 1.
Sex | Treatmenta | Body weight (g) at | Plasma concentrations of | ||
beginning | end | prolactin (ng/ml) | haloperidol (ng/ml) | ||
Male | haloperidol | 351.5 ± 6.9 | 476.0 ± 8.4 | 64.7 ± 43.7 | 4.3 ± 0.9b |
placebo | 342.5 ± 6.3 | 473.0 ± 9.5 | 37.3 ± 10.0b | 1.5, 2.0, <1.3c | |
Female | haloperidol | 211.0 ± 15.2 | 298.0 ± 16.9 | 441.1 ± 243.3 | ND |
placebo | 211.0 ± 12.9 | 300.0 ± 15.6 | 150.5 ± 112.7b | ND |
aEach group consisted of 10 rats.
bn = 5
cHaloperidol was below the detection limit in three of the five rats examined.
ND: not determined due to a high background activity of unknown origin.
Plasma concentrations of prolactin and haloperidol were determined by the [125I]-labelled radioimmunoassay and colloidal gold immunoassay, respectively.